Monopar Therapeutics Inc. (MNPR)
Nasdaq · Healthcare · Biotechnology
$78.29+0.41%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $526M
- 52-week range
- $50.07 – $124.82
- 52-week change
- −20.53%
- EPS (trailing)
- −$2.20
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$13.7M
From the company’s annual report on SEC EDGAR.
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Headquarters: Wilmette, United States · 22 employees · monopartx.com